Oculis: eye drops with Dexamethasone/gamma-CD complex Phase 3 study concluded soon
Oculis’s most advanced product candidate, OCS-01, is currently in Phase 3 development and aims to be the first eye drop
Tag: Oculis
Cyclodextrin scientists in the finals for European Inventor Award 2023
Inventors, who made a significant contribution to innovation, economy and society in Europe have been awarded since 2006 by the
Oculis goes public on the Nasdaq Stock Market
Oculis the Icelandic (now global) ophthalmology company, founded by Thorsteinn Loftsson and Einar Stefánsson, celebrated its public listing on the
OCULIS ANNOUNCES AN OVERSUBSCRIBED US$57 MILLION SERIES C FINANCING
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01
Novel dexamethasone formulation shows efficacy and safety with once-daily use
Eric D. Donnenfeld, a consultant to Oculis reported for Ophthalmology Times on the results of a phase 2 trial: dexamethasone
Oculis Successful End-Of-Phase 2 Meeting With The FDA, On Towards Phase 3
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently announced that they are progressing towards Phase 3 with OCS-01 in two
Oculis Top-Line data from Phase 2 clinical trial for OCS-01 treating inflammation and pain after cataract surgery
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently reported new clinical data at the Americal Society of Cataract and Refractive
Oculis aces the Phase 2 clinical trial for OCS-01 treating DME
Oculis reported positive results from Phase 2 clinical studies of OCS-01 for treating DME
Oculis started Phase II clinical trial with OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced